Roivant Sciences Ltd. (ROIV): Depreciation & Amortization
$3.35M
Year ended 2026-03-31
$2.85M
Trailing 12 months to 2026-06-30
-43.8%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $3.35M | -76.2% | 2026-05-20, From 2025-04-01 |
| 2025-03-31 | $14.07M | -36.1% | 2026-05-20, From 2024-04-01 |
| 2024-03-31 | $22.04M | +16.9% | 2026-05-20, From 2023-04-01 |
| 2023-03-31 | $18.86M | +217.9% | 2025-05-29, From 2022-04-01 |
| 2022-03-31 | $5.93M | n/a | 2023-06-28, From 2021-04-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $3.35M | -76.2% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $454.0K | -43.7% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $1.29M | -27.5% |
| Adagene Inc. (ADAG) | 2025-12-31 | $438.9K | -39.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $2.54M | -0.7% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $219.0K | +6.3% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $273.0K | -55.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $79.0K | -59.1% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $3.20M | -29.3% |
Compare ROIV, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗